Abstract
Domestic arthropods are chief sources of potent allergens that trigger sensitization and stimulate IgE-mediated allergies. Diagnosis and immunotherapy of arthropod allergies rely on the use of natural allergen extracts which are associated with low specificity and efficacy, the risk of anaphylactic reactions, and the extended period of treatment. Most of the problems associated with natural allergen extracts for allergy diagnosis and immunotherapy can be circumvented with the use of recombinant allergens and peptides. Recombinant allergens are recently developed for microarray-based multiallergen tests which provide component-resolved diagnosis (CRD) of the patients sensitization profile. Moreover, recombinant protein technology and peptide chemistry have been used to construct isoallergens, allergen mutants, allergoids, T and B cell peptides, hypoallergens, and mimotopes with reduced allergenicity but enhanced immunogenicity for allergenspecific immunotherapy (SIT) and vaccination. The basics of recombinant arthropod allergen technology are in place providing a lucid future for the advancement of diagnosis and immunotherapy of arthropod allergies.
Keywords: Allergy, recombinant allergens, arthropod allergens, hypoallergens, diagnostic reagents, therapeutic reagents
Protein & Peptide Letters
Title: Recombinant Proteins and Peptides as Diagnostic and Therapeutic Reagents for Arthropod Allergies
Volume: 14 Issue: 10
Author(s): John Donnie A. Ramos, Gardette R. Valmonte and Roldan M. de Guia
Affiliation:
Keywords: Allergy, recombinant allergens, arthropod allergens, hypoallergens, diagnostic reagents, therapeutic reagents
Abstract: Domestic arthropods are chief sources of potent allergens that trigger sensitization and stimulate IgE-mediated allergies. Diagnosis and immunotherapy of arthropod allergies rely on the use of natural allergen extracts which are associated with low specificity and efficacy, the risk of anaphylactic reactions, and the extended period of treatment. Most of the problems associated with natural allergen extracts for allergy diagnosis and immunotherapy can be circumvented with the use of recombinant allergens and peptides. Recombinant allergens are recently developed for microarray-based multiallergen tests which provide component-resolved diagnosis (CRD) of the patients sensitization profile. Moreover, recombinant protein technology and peptide chemistry have been used to construct isoallergens, allergen mutants, allergoids, T and B cell peptides, hypoallergens, and mimotopes with reduced allergenicity but enhanced immunogenicity for allergenspecific immunotherapy (SIT) and vaccination. The basics of recombinant arthropod allergen technology are in place providing a lucid future for the advancement of diagnosis and immunotherapy of arthropod allergies.
Export Options
About this article
Cite this article as:
Ramos A. John Donnie, Valmonte R. Gardette and de Guia M. Roldan, Recombinant Proteins and Peptides as Diagnostic and Therapeutic Reagents for Arthropod Allergies, Protein & Peptide Letters 2007; 14 (10) . https://dx.doi.org/10.2174/092986607782541150
DOI https://dx.doi.org/10.2174/092986607782541150 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Difficulties in Describing Allergic Disease Modulation by Pre-, Pro- and Synbiotics
Current Pharmaceutical Design Clinical and Forensic Signs Related to Cocaine Abuse
Current Drug Abuse Reviews Hypersensitivity Reactions to Neuromuscular Blocking Agents
Current Pharmaceutical Design Natural Rubber Latex Allergy in Pediatric Patients
Current Pediatric Reviews Telmisartan, its Potential Therapeutic Implications in Cardiometabolic Disorders
Recent Patents on Cardiovascular Drug Discovery New Antihypertensive Drugs Under Development
Current Medicinal Chemistry PF-04886847 (an Inhibitor of Plasma Kallikrein) Attenuates Inflammatory Mediators and Activation of Blood Coagulation in Rat Model of Lipopolysaccharide (LPS) - Induced Sepsis
Cardiovascular & Hematological Agents in Medicinal Chemistry A Review of Current Knowledge of the Complement System and the Therapeutic Opportunities in Inflammatory Arthritis
Current Medicinal Chemistry Drug Interactions with Angiotensin Receptor Blockers: Role of Human Cytochromes P450
Current Drug Metabolism The Effect of SEX/Gender on Cardiovascular Pharmacology
Current Pharmaceutical Design Current Indications for Infective Endocarditis Antibiotic Prophylaxis
Infectious Disorders - Drug Targets Antivenoms for Snakebite Envenomings
Inflammation & Allergy - Drug Targets (Discontinued) A Brief Review of the Essential Role of Nanovehicles for Improving the Therapeutic Efficacy of Pharmacological Agents Against Tumours
Current Drug Delivery Omalizumab: Not Only For Asthma
Recent Patents on Inflammation & Allergy Drug Discovery Hypersensitivity Reactions from Excipients in Systemic Glucocorticoid Formulations
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Bridging the Gap Between Chemistry and Biotechnology - Large Molecules with Potential, How Could Biotechnology Complement Chemistry?
Current Organic Chemistry Advances in Peptide Pharmaceuticals
Current Pharmaceutical Biotechnology Drug Hypersensitivity: Epidemiology and Risk Factors
Current Pharmaceutical Design A Systematic Review of Randomized Controlled Trials Examining the Nephroprotective Properties of Antihypertensive Medications
Current Hypertension Reviews Hypersensitivity to Aspirin and Other Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
Current Pharmaceutical Design